Comment from Novo Nordisk Inc.

Summary: Novo Nordisk, a global healthcare company, supports the FDA's Commissioner’s National Priority Voucher (CNPV) Pilot Program as a means to accelerate the development of treatments for national health priorities. The company requests greater transparency regarding selection criteria, expanded word limits for submissions, and flexibility in regulatory timelines to ensure a rigorous and predictable review process.